• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    President and CEO Romness Paul A. acquired 225,000 shares, increasing direct ownership by 10% to 2,473,000 units (SEC Form 4)

    2/28/25 6:03:39 PM ET
    $OSTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OSTX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Romness Paul A.

    (Last) (First) (Middle)
    C/O SHORE ACCOUNTANTS MD INC.
    115 PULLMAN CROSSING ROAD, SUITE 103

    (Street)
    GRASONVILLE MD 21638

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    OS Therapies Inc [ OSTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    02/28/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.001 per share 02/28/2025 J 225,000 A $0(1) 2,473,000 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Pursuant to a Transfer Agreement, effective as of May 13, 2024 (the "Transfer Agreement"), between Einodmil LLC ("Einodmil") and the reporting person, 600,000 shares of the issuer's common stock owned by the reporting person were placed in escrow in exchange for Einodmil's participation in a pre-IPO lock-up agreement. The Transfer Agreement, entered into in connection with the issuer's initial public offering, outlined conditions for distributing the 600,000 shares after expiration of the lock-up period, based on the 20-day VWAP of the issuer's common stock. On February 28, 2025, 225,000 of these shares were released from escrow and transferred to the reporting person. The remaining 375,000 shares were released from escrow and transferred to Einodmil.
    /s/ Paul A. Romness 02/28/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OSTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OSTX

    DatePrice TargetRatingAnalyst
    4/2/2025$19.00Buy
    Lake Street
    More analyst ratings

    $OSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on OS Therapies with a new price target

      Lake Street initiated coverage of OS Therapies with a rating of Buy and set a new price target of $19.00

      4/2/25 8:01:55 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    SEC Filings

    See more
    • SEC Form EFFECT filed by OS Therapies Incorporated

      EFFECT - OS Therapies Inc (0001795091) (Filer)

      6/9/25 12:15:23 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by OS Therapies Incorporated

      S-1 - OS Therapies Inc (0001795091) (Filer)

      5/23/25 4:51:41 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - OS Therapies Inc (0001795091) (Filer)

      5/16/25 4:05:12 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

      NEW YORK and CHICAGO, June 10, 2025 /PRNewswire/ -- OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, has selected EVERSANA®, a leading provider of global commercial services to the life sciences industry, to support the U.S. commercialization of OST-HER2, a novel immunotherapy for recurrent, fully resected, pediatric lung metastatic osteosarcoma. OST-HER2, a Listeria monocytogenes-based immunotherapy, is the first potential new treatment in over 40 years for pediatric os

      6/10/25 7:40:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

      If awarded, OST-HER2 would become the first listeria investigational medicinal product to be awarded the RMAT designation RMAT designation reduces BLA application review time and permits augmented interactions with FDA to inform market access OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. RMAT designations are granted to sponsors with regenerative

      6/6/25 7:30:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

      Feedback from Type D FDA Meeting expected by mid-June 2025 to confirm statistical analysis methods to support pending Accelerated Approval, Regenerative Medicine Advanced Therapy & Breakthrough Therapy designation requests Completed Phase 2b trial data analysis using methods agreed to by FDA to be presented at MIB Factor on June 28, 2025 Company remains on track for Q3 2025 BLA filing for OST-HER2 in the prevention of recurrent, fully resected, lung metastatic pediatric osteosarcoma OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported first quarter 2025 financial res

      5/16/25 6:00:00 AM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Former 10% Owner Auerbach Shalom

      4 - OS Therapies Inc (0001795091) (Issuer)

      5/9/25 9:45:04 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Auerbach Shalom sold $163,918 worth of shares (82,000 units at $2.00) (SEC Form 4)

      4 - OS Therapies Inc (0001795091) (Issuer)

      5/9/25 9:30:13 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Auerbach Shalom sold $81,566 worth of shares (60,012 units at $1.36) (SEC Form 4)

      4 - OS Therapies Inc (0001795091) (Issuer)

      4/11/25 9:45:07 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by OS Therapies Incorporated

      SC 13G - OS Therapies Inc (0001795091) (Subject)

      8/28/24 4:30:09 PM ET
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care